Enterprise Therapeutics Ltd.

Enterprise Therapeutics Ltd. is a British drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. According to its official website, the company focuses on diseases such as cystic fibrosis, asthma and COPD, in which the lungs become congested with mucus, leading to difficulty in breathing. Its scientific strategy is aimed at discovering new disease-modifying therapies that target the underlying mechanisms of mucus congestion, with the goal of reducing the frequency of lung infections and improving patient quality of life. The company's approach centres on muco-regulatory therapies achieved through targeting ion channels such as ENaC (epithelial sodium channel) to increase the hydration and clearance of mucus. Enterprise Therapeutics has also identified novel targets and compounds that reduce mucus production, an approach that complements its mucus hydration therapies. Its lead programme, the inhaled ENaC blocker ETD001, has progressed into clinical development for cystic fibrosis, with the company reporting a Phase 1 study published in The Journal of Cystic Fibrosis and, later, a primary efficacy outcome in a Phase 2 clinical trial. Enterprise Therapeutics is based in the United Kingdom, with offices at the University of Sussex Innovation Centre and in Blackfriars, London. It is backed by top-tier venture capital investors, including an international blend of leading corporate and more traditional venture investors such as Novartis Venture Fund, Versant, Forbion, IP Group and Epidarex. The company is led by a management team with significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology, and it works closely with leading scientific experts and world-renowned physicians involved in the development of new treatments for respiratory diseases. As a privately held, venture-backed biotechnology company, Enterprise Therapeutics does not trade on a public stock exchange. Its board includes both executive leadership and investor directors representing its venture capital backers, alongside a scientific advisory board of academic and clinical experts in respiratory medicine and cystic fibrosis.

Enterprise Therapeutics Ltd. is a UK-based drug discovery company focused on respiratory disease. According to its official website, the company was established to research and develop novel therapies for diseases in which the lungs become congested with mucus, including cystic fibrosis, asthma and COPD. It is headquartered in the United Kingdom, with offices at the University of Sussex Innovation Centre and in Blackfriars, London, and Wikidata describes it as a company in Brighton, United Kingdom. From its inception, Enterprise Therapeutics pursued a scientific strategy centred on muco-regulatory therapies — treatments intended to target the underlying mechanisms of mucus congestion rather than only its symptoms. The company's core approach targets ion channels such as ENaC to increase the hydration and clearance of mucus, with the aim of reducing the frequency of lung infections and improving patient quality of life. In parallel, the company identified novel targets and compounds that reduce mucus production, an approach that complements its mucus hydration therapies. The company has been financed by a syndicate of venture capital investors. Its official materials describe an international blend of leading corporate and more traditional venture investors, including Novartis Venture Fund, Versant, Forbion, IP Group and Epidarex. This investor base is reflected in the composition of the board, which includes investor directors from each of these firms alongside executive leadership and an independent chairman. Enterprise Therapeutics' lead programme is ETD001, a novel inhaled ENaC blocker being developed for the treatment of cystic fibrosis. The company published the medicinal chemistry of ETD001 in the European Journal of Medicinal Chemistry in November 2024. In December 2025, it published the results of a Phase 1 study of ETD001 in The Journal of Cystic Fibrosis, reporting that the compound was well tolerated in healthy individuals at higher doses. In May 2026, the company announced that it had achieved the primary efficacy outcome in a Phase 2 clinical trial of ETD001 in cystic fibrosis, describing it as the first investigational inhaled ENaC blocker to deliver clinically meaningful results in such a trial. Throughout its development, the company has worked closely with leading scientific experts and world-renowned physicians involved in the development of new treatments for respiratory diseases. Its scientific advisory board includes academic and clinical specialists in respiratory medicine and cystic fibrosis from institutions such as the University of North Carolina at Chapel Hill, Imperial College London, the University of Washington and others. Its management team is described as having significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology.

• Enterprise Therapeutics publishes on the medicinal chemistry of ETD001, a novel inhaled ENaC blocker for cystic fibrosis, in the European Journal of Medicinal Chemistry.

• Enterprise Therapeutics publishes results of the Phase 1 study of ETD001 in The Journal of Cystic Fibrosis, reporting it is well tolerated in healthy individuals at higher doses.

• Enterprise Therapeutics achieves the primary efficacy outcome in a Phase 2 clinical trial for cystic fibrosis with the novel inhaled ENaC blocker ETD001.

A venture-backed UK drug discovery company developing first-in-class inhaled muco-regulatory therapies for respiratory diseases, with a lead ENaC blocker programme in clinical development for cystic fibrosis.

• ETD001

  A novel inhaled ENaC blocker in development for the treatment of cystic fibrosis. It is described as the first investigational inhaled ENaC blocker to deliver clinically meaningful results in a Phase 2 cystic fibrosis trial.

• Muco-regulatory therapies

  Therapies targeting ion channels such as ENaC to increase the hydration and clearance of mucus, plus compounds targeting novel mechanisms to reduce mucus production.

• Unconfirmed

  Roche acquires Enterprise Therapeutics' TMEM16A potentiator portfolio[6]Roche 收购 Enterprise Therapeutics 的 TMEM16A 增效剂项目组合miragenews.com

  Roche acquired Enterprise Therapeutics' TMEM16A potentiator portfolio, which will be developed by Genentech, a member of the Roche Group. Enterprise shareholders are eligible for additional contingent payments tied to predetermined milestones.

Read more

1. 1Enterprise Therapeutics – Enterprise Therapeuticsenterprisetherapeutics.com
2. 2About Us – Enterprise Therapeuticsenterprisetherapeutics.com
3. 3Board – Enterprise Therapeuticsenterprisetherapeutics.com
4. 4Advisory Board – Enterprise Therapeuticsenterprisetherapeutics.com
5. 5Enterprise Therapeutics Ltd. (United Kingdom) – Wikidatawikidata.org
6. 6Roche 收购 Enterprise Therapeutics 的 TMEM16A 增效剂项目组合miragenews.com